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 Reaching the unreached and expecting the unexpected
March 24 marked annual World TB Day, this year’s theme 
being “reach the 3 million” who acquire tuberculosis every 
year but who do not get diagnosed, treated, or cured. Why 
do so many patients with this life-threatening infectious 
disease go under the radar? One reason, as Madhukar Pai 
and colleagues point out in a Comment this month, is that 
many people seek advice on their symptoms from care 
providers who have little to do with the evidence-based 
policies and procedures set out by national tuberculosis 
programmes. In some countries, such as India, half of 
patients with suspected tuberculosis are thought to 
visit private-sector medical services, under which use of 
appropriate diagnostics (including resistance testing), 
drugs, and follow-up cannot be guaranteed, and costs 
can be exorbitant. In other countries, services might be 
provided by a range of non-governmental organisations 
or by specialist public-sector entities (eg, army or prison 
health services) that operate out of the scope of national 
tuberculosis programmes.
WHO’s Stop TB Strategy already includes a public-
private mix (PPM) component, and many countries are 
implementing successful PPM initiatives to map out, 
engage, train, and monitor all types of provider. But Pai 
and colleagues suggest going beyond such a top-down 
strategy and taking a more business-like approach. They 
give examples of “patient-centric” solutions that involve 
innovations such as social enterprise and telemedicine, 
treat the whole patient, and are driven by “community 
champions”. As is so often the case in global health, the 
one-size-ﬁ ts-all approach is unlikely to provide all the 
answers, so adopting innovating solutions tailored to 
a region’s speciﬁ c situation seems sensible—as long as 
nationally led PPM eﬀ orts are not displaced.
Elsewhere in the issue, Petros Isaakidis and colleagues 
unfavourably compare the tuberculosis response with 
that of HIV/AIDS in terms of the dynamism of both the 
scientiﬁ c community and civil society. “It took less than 
30 years until aspirational goals of zero targets were set for 
HIV”, they point out. “Tuberculosis, a disease as ancient as 
the mummies, only fairly recently acquired such aspiring 
and ambitious targets.” Quite. Yet the reluctance to grab 
opportunities continues, it seems. While attending the 
International Congress on AIDS in Asia and the Paciﬁ c 
last November, Isaakidis and colleagues searched in vain 
for a session on “the number one killer of people with 
HIV”. Whether the presence of “zero TB” was down to 
the conference organisers or to abstract submitters, a 
tremendous opportunity seems to have been missed in 
a region home to more than half the world’s tuberculosis 
patients. 
The remarkable successes of the HIV/AIDS community 
are highlighted in the Article by Alain Vandormael and col-
leagues. The study provides reassurance that the ﬁ ndings 
of the landmark HPTN 052 treatment-as-prevention 
study, done as it was in the somewhat artiﬁ cial conditions 
of a randomised trial and among couples in stable 
relationships, hold true in a high-burden region of South 
Africa—KwaZulu-Natal—where stable, monogamous 
relationships are not the norm. The prospective cohort 
study used robust methods to show that higher 
antiretroviral coverage at the household level is associated 
with lower HIV incidence. The authors suggest that the 
results could encourage individuals to disclose their HIV 
status to partners, to seek treatment, and to adhere to 
it—all of which would be enormously welcome in a region 
where HIV incidence continues to be stubbornly high. 
Finally, to another event that took place on March 24—a 
meeting convened by WHO to discuss progress on the 
eradication of yaws. This neglected tropical disease, which 
causes non-tender, self-limiting ulcers in the primary 
stages, but which can lead to deforming bone lesions if 
untreated, was targeted for eradication by 2020 after a 
Lancet study found that single-dose oral azithromycin was 
as eﬃ  cacious as intramuscular benzylpenicillin against 
the causative organism, Treponema pallidum subspecies 
pertenue. The meeting participants heard progress reports 
on mass treatment campaigns from endemic countries 
and discussed ongoing challenges. One of those is raised by 
an Article in this month’s issue. Oriol Mitjà and colleagues 
show that, in a yaws-endemic community in Papua New 
Guinea, more than half the patients presenting with yaws-
like ulcers harboured an entirely diﬀ erent organism—
Haemophilus ducreyi. Although H ducreyi is also susceptible 
to azithromycin, its ability to develop resistance must be 
kept in mind during mass drug administration campaigns. 
Expecting the unexpected is clearly still the order of the 
day, even for diseases “as ancient as the mummies”.
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